



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلم



HANAA ALY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



HANAA ALY



**COMPARISON BETWEEN TADALAFIL AND
TAMSULOSIN IN RELIVING STENT RELATED
SYMPTOMS:
A RANDOMISED STUDY**
Thesis

**Submitted for Partial Fulfillment
of Master Degree in Urology**

Presented by

Mina Murad Riad
M.B.B.Ch

Under supervision of

PROF. DR. HANY MOSTAFA ABDALLAH
*Professor of Urology
Faculty of Medicine, Ain Shams University*

DR. MOHAMED HASSAN MOHAMED
*Lecturer of Urology
Faculty of Medicine, Ain Shams University*

*Faculty of Medicine
Ain Shams University
2021*

Acknowledgments

First and foremost, I must thank GOD for the guidance and power to do all that work until its end.

I also want to thank my thesis advisor *Prof. Dr. Hany Mostafa*, Professor of Urology Faculty of Medicine - Ain Shams University for his continuous guidance, his continuous support and his careful attention to all aspects of work and study; he really has a very careful, alert and wise mind.

I would also want to thank *Dr. Mohamed Hassan*, Lecturer of Urology Faculty of Medicine - Ain Shams University, for his kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.

I would also like to thank my **parents** for their continuous encouragement and support, hoping God to bless them forever.

I would also like to thank all the **patients**, by whom and for whom this work was done, thank you for your effort and dedication to participate in it. Without you this work would never have been done.

Mina Murad Riad

List of Contents

Title	Page No.
List of Tables.....	i
List of Figures.....	iii
List of Abbreviations.....	vi
Introduction.....	1
Aim of the Study.....	3
Review of Literature	
Anatomy of the Ureter.....	4
Physiology of the Ureter.....	6
Kidney and Ureteric stones.....	11
Management of Kidney and Ureteric stones.....	13
Ureteral Stent or Double J (DJ).....	27
Pharmacology of Tamsulosin.....	40
Pharmacology of Tadalafil.....	55
Patients and Methods.....	71
Results.....	95
Discussion.....	123
Conclusion.....	129
Summary.....	130
References.....	131
Arabic Summary.....	—

List of Tables

Table No.	Title	Page No.
Table (1):	Pharmacokinetics of tamsulosin.....	47
Table (2):	Pharmacokinetics of tadalafil.....	61
Table (3):	Comparison between the two studied groups according to age.....	96
Table (4):	Comparison between the two studied groups according to urinary symptoms before treatment.....	98
Table (5):	Comparison between the two studied groups according to urinary symptoms after treatment.....	99
Table (6):	Comparison between the two studied groups according to body pain before treatment.....	100
Table (7):	Comparison between the two studied groups according to body pain after treatment.....	101
Table (8):	Comparison between the two studied groups according to general health before treatment.....	102
Table (9):	Comparison between the two studied groups according to general health after treatment.....	103
Table (10):	Comparison between the two studied groups according to work performance before treatment.....	104

Table (11): Comparison between the two studied groups
according to work performance after
treatment.....105

Table (12): Comparison between the two studied groups
according to sexual matters before
treatment.....106

List of Tables cont. . .

Table No.	Title	Page No.
Table (13):	Comparison between the two studied groups according to sexual matters after treatment.....	107
Table (14):	Comparison between the two studied groups according to additional problems before treatment.....	108
Table (15):	Comparison between the two studied groups according to additional problems after treatment.....	109
Table (16):	Comparison between the two studied groups regarding ureteral stent symptoms questionnaire (USSQ) results before medical treatment.....	110
Table (17):	Comparison between the two studied groups regarding ureteral stent symptoms questionnaire (USSQ) results after medical treatment.....	111
Table (18):	Comparison between before (a week after DJ insertion) and after medical treatment (after 3 weeks) regarding ureteral stent symptoms questionnaire (USSQ) results in Group A (Tadalafil group).....	113
Table (19):	Comparison between before (a week after DJ insertion) and after medical treatment (after 3 weeks) regarding ureteral stent symptoms questionnaire (USSQ) results in Group B (Tamsulosin group).....	118

List of Figures

Fig. No.	Title	Page No.
Fig. (1):	Shock wave lithotripsy (SWL).....	20
Fig. (2):	Rigid URS.....	21
Fig. (3):	Flexible URS and basket.....	22
Fig. (4):	Percutaneous nephrolithotomy (PCNL).....	24
Fig. (5):	(A) Normal stent position (B) Stent displaced, crossing the midline with encrusted bladder coil of the stent.....	31
Fig. (6):	Potential clinical uses of tamsulosin in urological conditions other than benign prostatic hyperplasia.....	41
Fig. (7):	Location of phosphodiesterase type 5 (PDE5) isoenzymes in the lower urinary tract.....	57
Fig. (8):	Ureteral Stent Symptom Questionnaire (USSQ).....	84
Fig. (9):	Arabic translation of Ureteral Stent Symptom Questionnaire (USSQ).....	93
Fig. (10):	Bar charts show Comparison between the two studied groups as regard gender.....	97
Fig. (11):	Bar charts show Comparison between the two studied groups as regard age.....	97
Fig. (12):	Box plot show Comparison between the median (IQR) of the two studied groups as regard general health.....	112

List of Figures cont...

Fig. No.	Title	Page No.
Fig. (13):	Box plot show Comparison between the median (IQR) of the two studied groups as regard sexual matters.....	112
Fig. (14):	Box plot show Comparison between the median (IQR) before and after treatment of group A as regard urinary symptoms.....	115
Fig. (15):	Box plot show Comparison between the median (IQR) before and after treatment of group A as regard body pain.....	115
Fig. (16):	Box plot show Comparison between the median (IQR) before and after treatment of group A as regard general health.....	116
Fig. (17):	Box plot show Comparison between the median (IQR) before and after treatment of group A as regard work performance.....	116
Fig. (18):	Box plot show Comparison between the median (IQR) before and after treatment of group A as regard sexual matters.....	117
Fig. (19):	Box plot show Comparison between the median (IQR) before and after treatment of group A as regard additional problems.....	117
Fig. (20):	Box plot show Comparison between the median (IQR) before and after treatment of group B as regard urinary symptoms.....	120

List of Figures cont...

Fig. No.	Title	Page No.
Fig. (21):	Box plot show Comparison between the median (IQR) before and after treatment of group B as regard body pain.....	120
Fig. (22):	Box plot show Comparison between the median (IQR) before and after treatment of group B as regard general health.....	121
Fig. (23):	Box plot show Comparison between the median (IQR) before and after treatment of group B as regard work performance.....	121
Fig. (24):	Box plot show Comparison between the median (IQR) before and after treatment of group B as regard sexual matters.....	122
Fig. (25):	Box plot show Comparison between the median (IQR) before and after treatment of group B as regard additional problems.....	122

List of Abbreviations

Abb.	Full term
α	Alpha
β	Beta
AAG.....	Alpha-1-acid glycoprotein
Ach.....	Acetylcholine
AD.....	Alzheimer's disease
ATP.....	Adenosine triphosphate
AUA.....	American Urological Association
AUC.....	Area under the curve
BP.....	Blood pressure
BPE.....	Benign prostatic enlargement
BPH.....	Benign prostatic hyperplasia
C.....	Celsius
Ca ²⁺	Calcium ions
cAMP.....	Cyclic adenosine monophosphate
CaOx.....	Calcium oxalate
CaP.....	Calcium phosphate
CBC.....	Complete blood count
CBF.....	Cerebral blood flow
cc.....	Cubic centimetre
cGMP.....	Cyclic guanosine monophosphate channel 3
CKD	Chronic kidney disease
CLcr.....	Creatinine Clearance
cm.....	Centimeter
cm.....	Centimeter
Cmax.....	Maximum or peak concentration
CSCR.....	Central serous chorioretinopathy
CT.....	Computed tomography
CYP.....	Cytochrome P450
DAG.....	Diacylglycerol
EAU.....	European Association of Urology
ED.....	Erectile dysfunction
ESRD	End-stage renal disease
ESWL.....	Extracorporeal shockwave lithotripsy
F	French
FDA.....	Food and Drug Administration

List of Abbreviations cont...

Abb.	Full term
g/mol.....	Grams per mole
g.....	Gram
GI.....	Gastrointestinal
GPCR.....	G-protein-coupled receptor
G-protein.....	Guanine nucleotide-binding protein
H1-receptor.....	Histamine receptor type 1
HCl.....	Hydrochloride
HCN3.....	Hyperpolarization-activated cyclic nucleotide-gated
HNSCC.....	Head and neck squamous cell carcinoma
Ho: YAG.....	Laser holmium: yttrium-aluminium-garnet laser
HS.....	Highly significant
Hz.....	Hertz
i.e.....	In essence
ICC.....	Interstitial cells of Cajal
IFIS.....	Intraoperative floppy iris syndrome
IP3.....	Inositol trisphosphate
IQR.....	Interquartile range
IVU.....	Intravenous urography
K+.....	Potassium ions
KUB.....	Kidney, ureter and bladder radiography
L.....	Litre
LUTS.....	Lower urinary tract symptoms
M.....	Receptor muscarinic receptor
MDCT.....	Multi-detector Computed Tomography
meq.....	Milliequivalent
MET.....	Medical expulsive therapy
mg.....	Milligram
MI.....	Myocardial infarction
min.....	Minute
mL/min.....	Milliliters per minute
mm Hg.....	Millimetre of mercury
mm.....	Millimeter
MRI.....	Magnetic resonance imaging
mRNA.....	Messenger ribonucleic acid
MRU.....	Magnetic resonance urography
mV.....	Millivolt

List of Abbreviations cont...

Abb.	Full term
NAION.....	Non-arteritic anterior ischemic optic neuropathy
ng/ml.....	Nanograms per milliliter
NO.....	Nitric oxide
NS.....	Non significant
NSAIDs.....	Non-steroidal anti-inflammatory drugs
PAH.....	Pulmonary arterial hypertension
PCN.....	Percutaneous nephrostomy
PCNL.....	Percutaneous Nephrolithotomy
PDE5.....	Phosphodiesterase type 5
PH.....	Power of hydroge
PKC.....	Protein kinase C
PKGs.....	cGMP-dependent protein kinases
PLC.....	Phospholipase C
RBCs.....	Red blood cells
S.....	Significant
SD.....	Standard deviation
SFRs.....	Stone-free rates
SMCs.....	Smooth Muscle Cells
SPSS.....	Statistical Package for Social Science
SWL.....	Shockwave lithotripsy
T _{1/2}	Terminal plasma half-life
T _{max}	Time to maximum or peak concentration
UPJ.....	Ureteropelvic junction
URS.....	Ureteroscopy
URSL.....	Ureteroscopic lithotripsy
US.....	Ultrasound
USSQ.....	Ureteral Stent Symptom Questionnaire
UTI.....	Urinary tract infection
UVJ.....	Ureterovesical junction
VAS.....	Visual Analogue Scale
WBC.....	White blood count
WBCs.....	White blood cells